Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Biogen, Inc.
In this week's podcast edition of Five Must-Know Things: a slow start for Biogen’s Aduhelm; J&J looks to transition COVID vaccine to commercial sales; 2seventy bio spins out from bluebird bio; UCB faces bimekizumab delays; and progress and setbacks in gene therapy.
Brainsgate’s ISS500 can reportedly lessen stroke symptoms if put into use within 24 hours of the onset of symptoms.
Two products that were on the European Commission’s original list of the “top five” COVID-19 candidate therapeutics in development have been dropped from the latest “top 10” portfolio.
Analysts in Q3 pounced on a quirk in the complex US healthcare system that has provided small relief to Biogen’s much-depleted Tecfidera franchise in the US in the face of many generic rivals.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Biogen Idec
- Convergence Pharmaceuticals Ltd
- Nightstar Therapeutics plc
- Stromedix, Inc.
- Syntonix Pharmaceuticals